drug

alisertib

1 story · latest Aug 6, 2026

Status: Investigational
Codes: MLN-8237, MLN8237, PB-8237
Trials: 4 registered trials in coverage

Relationships

Developed by Puma Biotechnology, Inc.

Developed by Mayo Clinic

Timeline

Puma Biotechnology raises 2026 guidance on NERLYNX demand, details alisertib trial timeline

Aug 6Quarterly updatealisertib neratinib

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.